Artiva Biotherapeutics (ARTV) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier.
Four analysts surveyed by Capital IQ expected a loss of $4.40.
No revenue for the quarter ended June 30 was reported. Revenue a year earlier was $3.5 million.
Four analysts polled by Capital IQ estimated $80,000.
As of June 30, the company said it had $46.6 million in cash, cash equivalents, and short-term investments. It said the $179 million in gross proceeds from its initial public offering in July extends cash runway at least through the end of 2026 and through key clinical data milestones.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments